ArticleEuropean thyroid journal2025
Active surveillance for low-risk papillary thyroid microcarcinoma: a web-survey on clinician readiness for change.
Article in European thyroid journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Indications and Complications of Total Thyroidectomy in the Management of Thyroid Diseases: A Five-Year Retrospective Study in a Greek Population.Acta medica academica · 2026Article
- De-escalation implementation in low-risk papillary thyroid cancer: a nationwide survey.Endocrine connections · 2026Article
- Promise and pitfalls of AI chatbots in complex decision-making for thyroid nodules and papillary thyroid cancer.European thyroid journal · 2026Article
- Decision-making value of a 1-cm tumor diameter cut-off for postoperativeAmerican journal of translational research · 2026Article
- Nationwide web survey on implementing the 2023 ETA guidelines for second-line management thyroid nodules with atypia of undetermined significance.Hormones (Athens, Greece) · 2025Article
- Microwave ablation vs. surgery for thyroid microcarcinoma near the capsule: a propensity-matched study on safety and efficacy.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Current guidelines emphasize active surveillance (AS) over immediate surgery for low-risk papillary thyroid microcarcinomas (PTMCs). Alternative minimally invasive treatments, such as thermal ablation, are being explored. If thyroidectomy is performed, lobectomy is preferred and radioactive iodine (RAI) remnant ablation is not routinely recommended for low-risk PTMC patients. Aim: This study aimed to assess the approach of Greek endocrinologists toward AS and the management of low-risk PTMCs. Methods: A web-based survey was conducted among members of the Hellenic Endocrine Society (HES). Two clinical scenarios involving a 60-year-old woman with low-risk PTMC were analyzed. Surveyed endocrinologists were asked whether they would recommend AS, thermal ablation, lobectomy or total thyroidectomy as primary treatment; and if total thyroidectomy was performed in this case, whether they would recommend RAI ablation. Results: A total of 201 endocrinologists (25% of HES members) participated. As primary treatment for low-risk PTMC, 46.8% recommended total thyroidectomy, 31.3% chose AS, 20.9% opted for lobectomy and 1.0% selected thermal ablation. If total thyroidectomy was performed, 95% considered RAI ablation unlikely and only 5% would use RAI. Demographic characteristics, including age, sex, experience and geographic location, did not significantly influence these choices. The primary reason cited by endocrinologists for noncompliance is skepticism about implementing the guidelines, likely stemming from resource limitations and educational gaps. Conclusion: One-third of Greek endocrinologists prefer AS for managing low-risk PTMCs. More time and effort may be needed to further shift their clinical approach. Insights from our web survey aim to reduce overtreatment in low-risk PTMC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.